Claims for Patent: 11,712,442

Summary for Patent: 11,712,442

Title:	Dry powder treprostinil for the treatment of pulmonary hypertension
Abstract:	A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Inventor(s):	Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
Assignee:	Liquidia Technologies Inc
Application Number:	US17/104,348
Patent Claims:	1. A method of treating a patient in need thereof, comprising: administration of a dry powder composition comprising from about 5 milligrams to about 20 milligrams dry powder drug product to a patient by inhalation using a dry powder inhaler over one to two breaths to treat pulmonary hypertension or pulmonary arterial hypertension, wherein the dry powder drug product comprises treprostinil or a pharmaceutically acceptable salt thereof, and wherein the dry powder drug product comprises a fine particle fraction between about 82 percent and about 89 percent of the total dry powder drug product. 2. The method of claim 1, wherein the fine particle fraction remains between about 82 percent and about 89 percent of the total dry powder drug product when the dry powder drug product is stored for at least six months at 25° C. and 60% RH. 3. The method of claim 1, wherein the patient receives about 2.5 milligrams to about 5 milligrams dry powder drug product per breath. 4. The method of claim 1, wherein the patient receives about 5 milligrams to about 10 milligrams dry powder drug product per breath. 5. The method of claim 1, wherein the patient receives about 7.5 milligrams to about 15 milligrams dry powder drug product per breath. 6. The method of claim 1, wherein the patient receives about 12.5 micrograms to about 150 micrograms treprostinil or the pharmaceutically acceptable salt thereof per breath. 7. The method of claim 1, wherein the patient inhales the dry powder drug product four times a day. 8. The method of claim 1, wherein the patient receives between about 20 milligrams and about 80 milligrams dry powder drug product per day. 9. A method of treating a patient, comprising: providing to a patient having a condition of pulmonary hypertension or pulmonary arterial hypertension a dry powder inhaler and a plurality of drug capsules containing a dry powder drug product, each drug capsule of the plurality of drug capsules comprising a dose between about 25 micrograms and about 100 micrograms of treprostinil or a pharmaceutically acceptable salt thereof; and instructing the patient to inhale the dry powder drug product of each drug capsule of the plurality of drug capsules with the dry powder inhaler over one to two breaths to treat the condition, wherein the dry powder drug product comprises a fine particle fraction between about 82 percent and about 89 percent of the total dry powder drug product. 10. The method of claim 9, wherein the fine particle fraction remains between about 82 percent and about 89 percent of the total dry powder drug product when the dry powder drug product is stored for at least six months at 25° C. and 60% RH. 11. The method of claim 9, wherein the patient receives greater than about 12.5 micrograms treprostinil per breath. 12. The method of claim 9, wherein the patient receives about 12.5 to about 25 micrograms treprostinil per breath. 13. The method of claim 9, wherein the patient receives about 25 to about 50 micrograms treprostinil per breath. 14. The method of claim 9, wherein the patient receives about 37.5 to about 75 micrograms treprostinil per breath. 15. The method of claim 9, wherein the patient receives about 75 to about 150 micrograms treprostinil per breath. 16. The method of claim 9, wherein the dry powder drug product comprises about 25 micrograms treprostinil in about 5 milligrams dry powder drug product. 17. The method of claim 9, wherein the patient inhales the dry powder drug product four times a day. 18. The method of claim 9, wherein the patient receives between about 100 micrograms and about 400 micrograms treprostinil per day.